

Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy

Enoch Tin ^{1,2}, Ismat Khatri,¹ Karen Fang ^{1,3}, Yoosu Na,¹ Michele Nawata,^{4,5} Juan Arteaga,^{4,5} Mark D Minden,¹ Sergio Rutella ⁶, Jongbok Lee,^{4,5} Li Zhang^{1,2,3}

To cite: Tin E, Khatri I, Fang K, *et al.* Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy. *Journal for ImmunoTherapy of Cancer* 2025;13:e010684. doi:10.1136/jitc-2024-010684

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/jitc-2024-010684>).

Accepted 02 April 2025



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

¹University Health Network, Toronto, Ontario, Canada

²Immunology, University of Toronto, Toronto, Ontario, Canada

³Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

⁴Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada

⁵Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada

⁶John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK

Correspondence to

Dr Li Zhang;
li.zhang@uhnresearch.ca

ABSTRACT

Background Allogeneic double-negative T-cell (DNT) therapy has emerged as a novel, off-the-shelf cellular treatment with clinical feasibility, safety, and promising efficacy against leukemia. However, the biology of DNTs is less well characterized, and how DNT therapy distinguishes from conventional $\gamma\delta$ T-cell therapy remains unclear. Collectively, this hinders our ability to bolster DNT functionalities in cancer therapy. Here, we performed single-cell RNA sequencing with in vitro and in vivo functional analysis on DNTs. As a significant proportion of DNTs express V γ 9V δ 2 (V δ 2) TCR chain, we compared DNTs with donor-matched conventional V δ 2 T cells expanded with zoledronic acid.

Methods Healthy donor-derived allogeneic DNTs and V δ 2 T cells were expanded ex vivo. Single-cell RNA sequencing analysis was performed on both cellular products to identify the transcriptional landscape and inferred cellular interactions within DNTs, followed by comparisons with donor-matched V δ 2 T cells. Unique cellular subsets found only in DNTs were depleted to identify their contributions to the overall efficacy of DNTs against acute myeloid leukemia. The anti-leukemic activity and in vivo persistence of DNTs and V δ 2 T-cells were explored using flow cytometry-based cytotoxicity assays, memory phenotyping, and xenograft models.

Results Despite a shared V δ 2 expression between cellular products, we identified unique cellular compositions in DNTs that contribute to distinct transcriptional and cellular communication patterns relative to the donor-matched V δ 2 T cells, including higher expression of genes identified in chimeric antigen receptor T cells that persist in patients with durable cancer-remission. V δ 2⁺ DNTs exhibited strong persistence characteristics, and their presence promoted the cytotoxic capabilities of V δ 2⁺ DNTs in repeated stimulation assays. This unique genetic signature and diverse cellular composition of DNTs resulted in better overall ex vivo expansion, prolonged persistence, and superior anti-leukemic activity compared with V δ 2 T cells in vitro and in vivo.

Conclusions These results highlight the unique transcriptional, cellular, and functional profile of human DNTs and support the continued clinical investigation of allogeneic DNT therapy. The data also provide a reference gene signature that may help improve the efficacy of other types of allogeneic adoptive cellular therapies.

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Allogeneic double-negative T-cell (DNT) therapy demonstrates safety and potential efficacy in early-phase clinical trials. However, the biology of human DNTs is not well understood, which hinders its clinical applications.
- ⇒ A significant proportion of DNTs express V γ 9V δ 2 (V δ 2) TCR, and both DNTs and conventional V δ 2 T cells display off-the-shelf therapy characteristics for cancer treatment in separate studies. However, how they differ from each other, as adoptive cellular therapies, has never been investigated previously.

WHAT THIS STUDY ADDS

- ⇒ This is the first study to perform single-cell RNA sequencing on ex vivo expanded human DNTs and describe a unique DNT genetic signature relative to V δ 2 T cells.
- ⇒ Ex vivo expanded DNTs exhibit unique subpopulations that provide mechanisms for greater anti-leukemic function and prolonged persistence compared with zoledronic acid-expanded V δ 2 T cells.
- ⇒ Persisting chimeric antigen receptor (CAR) T cells with a DNT phenotype in patients, who achieved long-term remission, share transcriptional features with ex vivo expanded DNTs.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study supports the continued clinical investigation of using allogeneic, unmodified or CAR-transduced DNTs for treating leukemias and provides insights to improve the efficacy of DNTs and other types of adoptive cellular therapies.

INTRODUCTION

The successes of adoptive cellular therapy (ACT) have helped propel the field of immunotherapy as the fourth pillar of cancer treatment.¹ Current Food and Drug Administration-approved cellular therapies rely on patient-derived autologous T cells for chimeric antigen receptor (CAR) T-cell

treatment to avoid graft-versus-host disease (GvHD) and host-versus-graft (HvG) rejection.² Although impressive clinical outcomes are observed,³ autologous cellular therapies are associated with expensive costs and lengthy manufacturing times, which limit patient accessibility and overall therapeutic effectiveness.^{4,5} Thus, allogeneic cellular products as off-the-shelf therapies have been explored to reduce costs, democratize ACTs, and shorten treatment delivery time.⁵

Off-the-shelf allogeneic cellular therapies should ideally satisfy various clinical criteria such as scalability and limited GvHD and HvG rejection.⁶ To circumvent GvHD and HvG rejection, several studies have developed off-the-shelf allogeneic CAR T-cell therapies by genetic deletion of the T-cell receptor (TCR) alpha constant gene and other surface molecules such as CD52 to allow for alemtuzumab-mediated depletion of host lymphocytes.⁷ However, extensive gene editing increases cell manufacturing complexity and creates concerns around acquired genetic abnormalities.⁸ As such, allogeneic cellular candidates that do not require genetic alterations remain an attractive option, such as $\gamma\delta$ T cells and natural killer (NK) cells. These innate-like immune cells exhibit strong anti-tumor capabilities, especially against hematological malignancies such as acute myeloid leukemia (AML), without inducing GvHD in allogeneic settings.⁹ Despite the widely accepted safety profile, clinical trials using $\gamma\delta$ T cells and NK cells show inconsistent efficacy among patients with AML and highlight the likely need to increase cellular persistence in vivo for prolonged anti-leukemic effects.^{9–12}

Double-negative T cells (DNTs) have emerged as another promising candidate among off-the-shelf therapies.⁶ Comprising 1%–3% of peripheral leukocytes, these mature T lymphocytes are CD3⁺CD4[−]CD8[−] and lack invariant NK T-cell and mucosal-associated invariant T-cell markers.^{6,13} Without genetic modifications, ex vivo DNTs can expand to clinically relevant levels and target primary AML cells in preclinical models without the occurrence of GvHD and HvG rejection.^{6,13} Furthermore, the feasibility, safety, and potential efficacy of allogeneic DNT therapy were demonstrated in a phase I clinical trial in patients with high-risk AML.¹⁴ DNT effector function can also be expanded with CAR transduction^{15,16}; this approach has demonstrated promising anti-tumor activity and safety in a recent phase I clinical trial with allogeneic CD19-directed CAR DNTs for patients with high-grade lymphoma.¹⁷ However, long-term tracking of allogeneic DNTs was not performed in the clinical trials. Interestingly, several clinical studies have reported that persisting CAR-expressing T cells in patients with long-term cancer remission are significantly enriched with a DNT phenotype, despite their low frequency in the initial infused treatment product.^{18–20} This suggests potential intrinsic therapeutic properties unique to DNTs, leading to robust anti-cancer effects and better clinical outcomes. Despite advances in clinical applications of DNTs, their biology is poorly understood.

In this study, we characterized human DNTs through single-cell RNA sequencing (scRNA-seq) and in vitro and in vivo functional studies. Given that a majority of DNTs express V γ 9V δ 2 (V δ 2) TCR, the therapeutic properties of DNTs and conventional V δ 2 T cells expanded using distinct protocols were compared. We discovered a unique transcriptional profile and strong cellular communication networks in DNTs, especially in clusters with V δ 2⁺ cells exclusively found in DNTs. These features corresponded to a greater ex vivo expansion and persistent anti-leukemic response against AML, compared with conventional V δ 2 T cells. These data provide insights into DNT therapy and a gene signature reflecting durable anti-cancer effects that are highly desirable for cellular therapies.

METHODS

scRNA-seq analysis

Day 14 DNTs and donor-matched V δ 2 T cells were sent for scRNA-seq in accordance with the standard protocol of the Chromium Single Cell 5' Kit (v2 chemistry) at the Princess Margaret Genomics Centre. A TCR single-cell library was subsequently prepared from the same cells with the Chromium Single Cell V(D)J Enrichment Kit. The 5' gene expression and TCR library were pooled for sequencing on Illumina NovaSeq, aiming for an average of 50,000 reads per cell. Raw scRNA-seq data were mapped to reference genome GRCh38 using Cell Ranger (V.6.1.2; 10x Genomics) (online supplemental file 2). To filter low-quality cells, we removed genes that were detected in less than 3 cells and cells that had fewer than 100 genes. Next, Scater and scDbiFinder packages were used for filtering and doublet identification, respectively. Seurat objects were normalized using SCTransform with default parameters, followed by principal component analysis. SCTransform-normalized datasets were integrated with Harmony²¹ (V.1.1.0) to remove batch effects. The number of principal components was set to 30, and clustering and the uniform manifold approximation and projection dimensionality reduction technique were performed.

12,977 cells were considered for downstream analysis using Seurat (V.5.0.1) with scRepertoire (V.2.1.0) for TCR analysis. Module scores were calculated using the AddModuleScore() function in Seurat and quantitatively presented with violin plots using clusters with scores >0 (T-cell signatures) or top scoring 1–2 clusters (persistent CAR-DNT signatures) due to sparsity. Gene ontology (GO) analysis on enriched genes (avg Log_{FC}>0.5) was performed using over-representation analysis and gene set enrichment analysis functions from the ClusterProfiler package,²² and GO gene sets were provided by MSigDB (<https://www.gsea-msigdb.org/gsea/msigdb/>). Predicted cellular interactions were modeled using the CellChat package²³ with default settings. The number of cellular patterns (4) was determined by a drop in Cophenetic and Silhouette values (online supplemental figure

S1).²³ Other visualization packages include Enhanced-Volcano (V.1.20.0), scCustomize (V.2.1.2), and Complex-Heatmap (V.2.20.0).

Ex vivo expansion of DNTs and Vδ2 T cells

DNTs were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors through CD4⁺ and CD8⁺ depletion cocktail (StemCell Technologies) followed by density centrifugation (Lymphoprep; StemCell Technologies). Enriched DNTs were expanded ex vivo using anti-CD3 (5 µg/mL plate-bound or 0.1 µg/mL soluble, OKT3; BioLegend), IL-2 (250 IU/mL, Proluekin; Novartis Pharmaceuticals), PI3Kδ-inhibitor idelalisib (1 µM; Selleck-Chem), and AIM-V media (ThermoFisher), as previously described.^{6,13,24} Ex vivo expansion of Vδ2 T cells was based on Kondo *et al.*'s protocol.²⁵ Briefly, PBMCs were isolated from healthy donors and cultured in CTS OpTmizer T cell Expansion media (ThermoFisher) with IL-2 (500 IU/mL, Proluekin; Novartis Pharmaceuticals), and zole-dronic acid (5 µM; Marcan Pharmaceuticals) on day 0, followed by fresh media and IL-2 every 3–4 days until day 20. Effector cells from days 10–20 of culture were used in the experiments.

Flow cytometry-based in vitro cytotoxic assays

Ex vivo expanded DNTs and Vδ2 T cells were co-cultured with AML cell lines for 2 or 24 hours to measure the cytotoxic activities of effector cells. The effector-to-target (E:T) ratios are indicated in the figure legends. AML viability was determined by Annexin V in CD3⁺CD33⁺ gated populations for AML cell lines. Percentage-specific killing was calculated by $\frac{\% \text{ AnnexinV}^+ \text{ with DNTs} - \% \text{ AnnexinV}^+ \text{ without DNTs}}{100 - \% \text{ AnnexinV}^+ \text{ without DNTs}} \times 100\%$.

Xenograft model

Female NOD.Cg-Prkdc^{scid}Il2rg^{tm1Wjl}/SzJ (NSG) mice, aged 8–12 weeks, (Jackson Laboratories) were used for all xenograft experiments and maintained by UHN animal facility in the same room. 5–10 mice were randomly allocated to each treatment group, and each experiment was performed at least two times. The sample size was decided to determine the reproducibility and statistical significance of the findings. There was no exclusion of experimental mice unless they reached the humane endpoint of 20% loss in original body weight, requiring sacrifice. Data collection was conducted in a blinded manner.

For AML xenograft models, mice were sublethally irradiated (225 cGy) 1 day prior to an intravenous injection of 1–1.5 × 10⁶ MV4-11 cells. Afterward, 2 × 10⁷ DNTs or Vδ2 T cells were intravenously injected on days 2, 5, and 8. 10⁴ IU rIL-2 (Proleukin) was given intravenously at the time of DNT or Vδ2 T cell infusion. Mice were euthanized 24–25 days after the last DNT or Vδ2 T cell infusion. 2–5 mice from each group were collected twice a week, to avoid over-bleeding of an individual mouse, until the end of the experiment for persistence tracking purposes. Cells from mice femurs were harvested to assess the bone

marrow engraftments of AML cells and were analyzed using flow cytometry.

For in vivo T-cell persistence studies, sublethally irradiated (225 cGy) mice were intravenously injected with 2 × 10⁷ of DNTs or Vδ2 T cells and 1 × 10⁶ allogeneic PBMCs. 10⁴ IU rIL-2 was given 1 week after the DNT or Vδ2 T-cell infusion. HLA-A2 expression mismatch between donors was used to distinguish between ex vivo expanded effector cells and allogeneic PBMCs (online supplemental figure S2). Mouse peripheral blood was collected twice a week until the end of the experiment and was analyzed by flow cytometry.

Mixed lymphocyte reaction

The ability of DNTs and Vδ2 T cells to suppress alloreactive CD8⁺ T cells was assessed using mixed lymphocyte reaction, as previously described.¹⁵ Briefly, PBMCs were co-cultured with or without allogeneic DNTs and Vδ2 T cells, in the presence or absence of irradiated (3000 cGy) DNTs as stimulators for 6 days at a ratio of 4:1:4 (allogeneic DNTs/Vδ2 T cells: irradiated DNT targets: PBMCs). CD8⁺ T cells from the co-cultures were isolated using a CD8⁺ selection kit (StemCell Technologies) and were used as effector cells against live, allogeneic, DNT targets in an overnight cytotoxicity assay at an E:T ratio of 1:1. After the co-culture, the viability of the target cells was determined by Annexin V staining and flow cytometry.

Statistical analysis

All graphs and statistical analyses were generated using GraphPad Prism V.5 and R. Paired and unpaired Student's t-test, one-way and two-way ANOVA, Fisher's exact test, and Wilcoxon signed-rank test were used. Bonferroni correction was used for multiple comparisons. nd=not detected, ns=nonsignificant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 indicate statistical significance between groups. Error bars represent mean ± SEM or ± SD.

RESULTS

Characterization of human DNTs by scRNA-seq

Despite observing the successful use of allogeneic DNT therapy in preclinical and clinical settings,^{6,14,15,17} the biology of human DNTs is poorly understood. Therefore, we performed scRNA-seq on ex vivo expanded DNTs from three healthy donors and revealed 14 DNT clusters (figure 1A). ScRNA-seq detected high expression of CD3 (*CD3G*) with minimal expression of CD4, CD8 (*CD8A* and *CD8B*), CD56 (*NCAM1*), and CD19 (figure 1B). Exploring the γδTCR and αβTCR profile, we detected *TRDV1* in three clusters (clusters 0, 4, and 12), *TRDV2* in all clusters except cluster 9 (figure 1B), and predominantly αβTCR⁺ cells with unique, individual αβTCR clonotypes in cluster 9 (figure 1C). *TRDV3* was not detected in any cluster (online supplemental figure S3).

Given the cellular therapeutic differences between Vδ1⁺ and Vδ2⁺ cells and a limited understanding of




Figure 1 Characterization of human DNTs by single-cell RNA sequencing. (A) Integrated UMAP plot of ex vivo expanded DNTs from three different donors. (B) Scaled average expression of *CD3G*, *CD4*, *NCAM1* (*CD56*), *CD8A*, *CD8B*, *CD19*, *TRDC*, *TRDV1*, and *TRDV2* in DNT clusters shown by violin plot. (C) Integrated UMAP plot of $\alpha\beta$ TCR expression and clonotype frequencies in DNTs. (D–H) Top differential gene markers (\log_2 FC>2) in DNT cluster 0 (D), cluster 4 (E), cluster 12 (F), cluster 9 (G), and clusters 1/2/3/5/6/7/10 (H). (I) Representative flow plot (left) and average relative abundance of different TCR subsets in ex vivo expanded DNTs (n=22). DNTs, double-negative T-cell; UMAP, uniform manifold approximation and projection.

$\alpha\beta$ TCR⁺ DNTs at the genetic level,²⁶ top gene markers (\log_2 FC>2) for specific DNT clusters were identified, excluding the small NK-cell and B-cell populations (clusters 11 and 13) (figure 1B). Cluster 0, comprised V δ 1⁺, V δ 2⁺, and $\alpha\beta$ TCR⁺ DNTs, exhibited high expression of genes associated with naïve and memory T-cell (*MAL* and *LEFI*)^{27 28} and immune co-stimulatory (*CD79A* and *CD27*)^{29 30} markers (figure 1D). Cluster 4, which had a small population of *TRDV1*⁺ cells, shared similar expression patterns as *TRDV2*⁺ clusters 1, 6, and 10 with several cell division genes (*CDCA2*, *CDCA3*, *CDCA8*, and *CDC25C*), FAM family genes (*FAM83D* and *FAM72B*), and kinesin family genes (*KIF14*, *KIF18B*, *KIF20A*, and *KIF23*) (figure 1E). Cluster 12, predominantly comprised of V δ 1⁺ cells, expressed various killer cell-like receptors (KLRs; *KLRC2*, *KLRC3*, *KIR2DL2*, and *KIR2DL4*), chemokine ligands (*CCL3*, *CCL4*, and *CCL4L2*), and exhausted T (T_{EX}) cell or regulatory T (T_{REG})-cell markers (*ENTPD1* and *TIGIT*)^{20 31 32} (figure 1F). Notably, V δ 1 chains of cluster 0, 4, and 12 mainly paired with the V γ 4/5/9, V γ 3/4/5/7, and V γ 2/8 chains, respectively (online supplemental figure S4), in which V γ 4V δ 1 and V γ 2V δ 1 T cells have potential persistent cancer-killing properties in patients.^{18 33} Cluster 9, the major group of $\alpha\beta$ TCR⁺ DNTs, was enriched with a chemokine receptor (*CCR6*), T-cell co-stimulatory molecule (*JAML*),³⁴ *KLRB1* and metabolic immune checkpoint marker (*IL4I1*)³⁵ (figure 1G). Other high-expressing molecules but with lesser-known functions related to T cells were detected, such as *LST1* (leukocyte specific transcript 1), *AQP3* (aquaporin 3), and *CCNG2* (cyclin G2) (figure 1G).

Given the wide expression of V δ 2 among DNTs, seven clusters with the highest *TRDV2* expression (clusters 1–3, 5–7, 10; online supplemental table S1) were grouped together and compared with all other clusters to identify top differential markers. These clusters collectively expressed *TRGV9* (figure 1H), commonly paired with the V δ 2 chains.²⁶ Clusters 2/5/7 exhibited expression of cytotoxic markers (*GZMB*, *GZMH*, and *GZMK*), KLRs (*KLRC1*, *KLRD1*, *KLRG1*, and *KLRB1*), and the *LAG3* exhaustion marker,²⁰ whereas clusters 1, 6, and 10 showed comparatively weaker expression (figure 1H). Cluster 3 had high expression of *LAG3* and multiple HLA molecules (*HLA-DQA2*, *HLA-DQA1*, and *HLA-DRB5*) (figure 1H). This suggests functional heterogeneity even among *TRDV2*^{high} DNTs. Using flow cytometry, these major DNT subsets were consistently observed on average among 22 donors whereby V δ 2⁺ DNTs had the highest average relative abundance (61.3%), followed by V δ 1⁺ DNTs (23.4%) and $\alpha\beta$ TCR⁺ DNTs (15.3%) (figure 1I).

DNT subsets are associated with unique transcriptional gene sets and patterns that support the overall DNT anti-leukemic function

With these distinct transcriptional differences between DNT clusters, we explored the inferred cellular

communication patterns between each cluster. A high number and strong levels of interactions were observed between all DNT clusters (online supplemental figure S5), with V δ 1-expressing clusters 4 and 12 displaying the highest predicted incoming and outgoing signals (figure 2A). To investigate potential functional differences between clusters, we first identified incoming (figure 2B) and outgoing (figure 2C) communication patterns. The partial V δ 1⁺ cluster 0 and $\alpha\beta$ TCR^{dominant} cluster 9 shared incoming patterns related to T-cell co-stimulation (*CD80* and *CD86*, pattern 3; figure 2B)³⁶ and outgoing patterns associated with NF- κ B activators (*CD30* and lymphotoxin, pattern 4; figure 2C).^{37 38} The V δ 1⁺ cluster 12 and NK-cell-dominant cluster 11 featured incoming T-cell activation (*PVR* and *CD226*, pattern 2; figure 2B)³⁹ and outgoing regulatory (*CD39* and *TIGIT*, pattern 1; figure 2C)^{20 31 32} patterns. Predominantly V δ 2⁺ clusters 1/4/6/8 exhibited proinflammatory incoming (*COMPLEMENT*, *MHCI*, *IL-2*, *IL-4*, pattern 1; figure 2B) and outgoing (*MHCI*, *MHCII*, *IL-1*, *IL-2*, *IL-4*, pattern 2; figure 2C) patterns. The B-cell^{dominant} cluster 13 featured distinct outgoing signals compared with other clusters (figure 2C), which validated our analysis. Next, we explored differentially expressed markers between V δ 2⁺ and V δ 2⁻ DNTs and observed that *TRDV2*⁺ DNTs were enriched with cytotoxic molecules (*GZMB*, *GZMH*, and *GNLY*) and NK receptors (*NKG7* and *KLRD1*), while *TRDV2*⁻ DNTs featured naïve and memory T-cell markers (*MAL* and *LEFI*)^{27 28} and co-stimulatory molecule *CD27*³⁰ (online supplemental figure S6). GO analysis also indicated an enrichment of cytotoxic and T-cell activation pathways in V δ 2⁺ DNTs, in contrast to cellular differentiation and regulation pathways found among V δ 1⁺ and $\alpha\beta$ TCR⁺ DNTs (figure 2D), suggesting an anti-tumor and help-like function between V δ 2⁺ and V δ 2⁻ DNT subsets, respectively.

V δ 2⁻ subsets in DNTs support DNT persistence and V δ 2⁺ DNT effector function against AML

To functionally validate the contributions of the major DNT subsets in the anti-AML response, we first assessed the expression of inflammatory cytokines (IFN γ and TNF α) and cytotoxic markers (granzyme B, CD107a, and TRAIL) in each DNT subset following co-culture with AML cell lines. V δ 2⁺ DNTs exhibited significantly higher intracellular IFN γ and TNF α levels compared with V δ 1⁺ and $\alpha\beta$ TCR⁺ DNTs during AML co-incubation (figure 2E and online supplemental figure S7). V δ 2⁺ DNTs expressed high levels of granzyme B in the presence or absence of AML cells (figure 2F). While V δ 1⁺ DNTs expressed significantly lower levels of granzyme B in the absence of AML cells, their granzyme B expression level became comparable to V δ 2⁺ DNTs after co-culture with MV4-11 (figure 2F). In addition, the degranulation marker CD107a was highest in V δ 2⁺ DNTs, followed by V δ 1⁺ then $\alpha\beta$ TCR⁺ DNTs, after co-culture with AML cells (online supplemental figure S8A). We did not observe significant differences in the expression of another




Figure 2 DNT subsets are associated with unique transcriptional gene sets and patterns that support the overall DNT anti-leukemic function. (A) Scatter plot of the inferred interaction strength between clusters in DNTs (n=3). Each dot represents a DNT cluster. (B, C) Predicted incoming (B) and outgoing (C) cellular ligand-receptor patterns among clusters in DNTs. Clusters were grouped into specific communication patterns based on similar inferred ligand-receptor networks. These networks are fully listed on the left of the heatmap, and specific networks are highlighted on the right of the heatmap. (D) Over-representation Gene Ontology analysis of enriched genes among DNTs expressing different TCRs (\log_2 FC *TRDV1* > 1, \log_2 FC *TRDV2* > 1, and $\alpha\beta$ TCR⁺ cluster 9 with \log_2 FC > 0.05). Top 10 enriched gene pathways are shown. Fisher's exact test was used for statistics. (E) Ex vivo expanded DNTs (n=3) were co-cultured with or without AML cell lines for 2 hours at an E:T ratio of 1:1 and stained for intracellular TNFα and IFNγ. A representative flow plot and summarized bar graph of TNFα⁺IFNγ⁺ cells by each subset of DNTs are shown. Paired dots indicate subsets from the same donor. One-way ANOVA was used for statistics. (F) DNTs (n=4) were co-incubated with or without MV4-11 for 4 hours at an E:T ratio of 1:1 and stained for granzyme B. Paired dots indicate subsets from the same donor. One-way ANOVA was used for statistics. (G) DNTs were cultured alone or with MV4-11 at an E:T ratio of 1:1 for up to 4 days (rounds). Fresh MV4-11 was added every 24 hours (rounds) at the original ratio. The change in subset frequency relative to the DNT alone group was assessed. Data shown are pooled results from two biological replicates. Mean±SD is displayed. Two-way ANOVA was used for statistics. (H) DNTs (n=3) were stimulated for 2 hours (round 1) or 3 days (round 3) with MV4-11 at an E:T ratio of 1:1 and stained for intracellular TNFα and IFNγ. Fresh MV4-11 was added every 24 hours (rounds) at the original ratio. Paired dots indicate subsets from the same donor. Paired Student's t-test was used for statistics. (I, J) DNTs were depleted of Vδ1⁺ cells, αβTCR⁺ cells, Vδ1⁺ and αβTCR⁺ cells, or mock sorted as a control. The depleted or control groups were co-cultured with MV4-11 at an E:T ratio of 1:1. Fresh MV4-11 was added every 24 hours (rounds) at the original ratio. The number of live MV4-11, representative of three independent experiments each performed with triplicates, is displayed (I). Intracellular TNFα, IFNγ, and CD107a in Vδ2⁺ DNTs were measured on round 3 stimulation for Vδ1/αβTCR-depleted DNTs and control DNTs (J). Paired dots indicate subsets from the same donor. Two-way ANOVA and paired Student's t-test were used for statistics. *p<0.05, **p<0.01, ***p<0.001. ANOVA, analysis of variance; DNT, double-negative T-cell; E:T, effector-to-target.

cytotoxic molecule, TRAIL, across different DNT subsets with or without AML cells (online supplemental figure S8B).

Next, we evaluated the role of different DNT subsets on the durability of anti-AML activity mediated by DNTs. During repeated stimulation assays with MV4-11, we observed a decrease in Vδ2⁺ DNTs frequency and total cell count, whereas the frequency of Vδ1⁺ DNTs increased and αβTCR⁺ DNTs remained relatively stable (figure 2G and online supplemental figure S9). Furthermore, we observed a marked reduction in IFNγ and TNFα production by Vδ2⁺ DNTs between their initial co-culture with AML cells compared with the third round of repeated stimulation (figure 2H). Collectively, these results demonstrate that while Vδ2⁺ DNTs play a crucial role in mediating immediate anti-leukemic response, their function is relatively short-lived and suggests that Vδ1⁺ and αβTCR⁺ DNTs are important for the durable anti-leukemic activity of the DNT product.

The prior cell interaction and GO analysis results suggested Vδ1⁺ and αβTCR⁺ DNTs may provide T-cell co-stimulatory and regulatory signals to the primarily cytotoxic Vδ2⁺ DNTs (figure 2A–D). To functionally evaluate the role of these DNT subsets, we depleted Vδ1⁺, αβTCR⁺, or both subsets from DNTs (online supplemental figure S10) and compared their function in a repeated stimulation assay relative to a mock-sorted DNT group as a control. Removing both Vδ1⁺ and αβTCR⁺ DNTs most significantly impaired the DNT-mediated anti-AML response (figure 2I). This impairment was partially attributed to reduced DNT proliferation in the Vδ1/αβTCR-depleted group during repeated stimulation, compared with control DNTs (online supplemental figure S11). In the absence of these subsets, Vδ2⁺ DNTs also displayed a lower frequency of IFNγ⁺TNFα⁺ cells and decreased expression of the degranulation marker CD107a by the third round of AML restimulation (figure 2J). Collectively, these findings highlight the transcriptional and functional differences among DNT subsets and their cooperative interactions that contribute to an overall more durable anti-AML response.

DNTs proliferate faster and transcriptionally differ from conventional Vδ2 T cells expanded with zoledronic acid

A significant proportion of DNTs express the Vδ2 TCR chain. To better understand the differences between DNTs and conventional γδ T cells, Vδ2 T cells were expanded ex vivo using standardized methods involving zoledronic acid²⁵ in parallel with donor-matched DNTs, and their transcriptional and functional differences were compared. Based on scRNA-seq and flow cytometry analyses, DNTs and Vδ2 T cells shared similar defining surface markers (CD3⁺CD4⁺CD8⁺CD56^{low/-}CD19⁺Vδ2⁺), except for prominent Vδ1⁺ and αβTCR⁺ populations found in DNTs (figures 3A–C and figure 1I, online supplemental figure S12). Moreover, DNTs had an average 2.8× greater expansion (n=6; figure 3D, left) and average 2.6× greater yield (n=6; figure 3D, middle) than their donor-matched

Vδ2 T cells and maintained a higher purity based on respective cellular definitions (DNTs: CD3⁺CD4⁺CD8⁺, Vδ2 T cells: CD3⁺γδTCR⁺; figure 3D, right).

To examine differences between DNTs and conventional Vδ2 T cells as well as Vδ2⁺ cells from both cellular products (online supplemental figure S13), top gene markers were identified for bulk and *TRDV2*⁺-specific comparisons between DNTs and Vδ2 T cells. DNTs expressed higher levels of *TRDV1*, as expected, along with the *CD28* co-stimulatory molecule (figure 3E, top) relative to Vδ2 T cells. Notably, both comparisons using bulk samples or *TRDV2*⁺ DNTs and Vδ2 T cells showed that DNTs exhibited higher levels of genes associated with T-cell memory (*Sell* and *IL7R*)²⁰ and *HSF4* (heat shock transcription factor 4; figure 3E). Furthermore, higher levels of *FOXP3* were detected in the *TRDV2*⁺-specific and bulk comparisons (figure 3E), a key transcription factor in T_{Reg} cells²⁰ that may provide DNTs with immunosuppressive characteristics. *TRDV2*⁺ DNTs were also enriched in gene pathways related to negative apoptosis regulation, growth, T-cell differentiation (figure 3F), and response to hypoxia (online supplemental figure S14). In contrast, Vδ2 T cells, expanded with zoledronic acid, expressed more immune activation receptors (*FCGR3A* and *KIR2DL4*; figure 3E), corresponding to enriched expression of myeloid-leukocyte activation genes (figure 3F). Furthermore, DNTs had greater levels of inferred cellular interactions and interaction strength compared with Vδ2 T cells when selecting for only *TRDV2*⁺ cells (figure 3G, left) or the bulk sample of both products (figure 3G, right). Overall, higher incoming and outgoing interactions were observed in DNT clusters compared with respective Vδ2 T-cell clusters (figure 3H).

DNTs feature greater co-stimulatory patterns and cytotoxicity against AML relative to Vδ2 T cells

When assessing the inferred interactions between bulk or *TRDV2*⁺ DNTs and Vδ2 T cells, we found pathways associated with the regulation of immune activation and cell adhesion that were unique or over-represented in DNTs (figure 4A and online supplemental figure S15). Specifically, we observed elevated signaling networks related to canonical T-cell expansion, effector function (IL-2; figure 4B) and co-stimulation (CD80/86; figure 4C and online supplemental figure S15) in DNTs compared with Vδ2 T cells.³⁶ Interestingly, IL-2 was not a significant communication network in the *TRDV2*⁺ comparative analysis while found in the bulk comparison, suggesting that Vδ2⁺ DNTs are providing additional IL-2 signals. Similarly, GO analysis of top markers in DNTs, relative to Vδ2 T cells, revealed an enrichment of proliferative gene sets (figure 4D), in line with expansion data (figure 3D) and the enriched growth genes observed in *TRDV2*⁺ DNTs (figure 3F).

The anti-leukemic function of DNTs and Vδ2 T cells has been independently reported but has not been directly compared in parallel.^{6,40} Although both cellular products express cytotoxic molecules (*PRF1*, *GZMA*, *GZMB*; Online




Figure 3 DNTs proliferate faster and transcriptionally differ from conventional Vδ2 T cells expanded with zoledronic acid. (A) Integrated UMAP plot of DNTs and donor-matched Vδ2 T cells expanded ex vivo (n=2 for each cell type). (B) Scaled average expression of *CD3G*, *CD4*, *NCAM1* (CD56), *CD8A*, *CD8B*, *TRDV1*, and *TRDV2* in DNT and Vδ2 T-cell clusters shown by violin plot. (C) Integrated UMAP plot showing the αβTCR repertoire profile in DNTs and Vδ2 T cells. (D) Expansion fold (left), yield (middle), and purity (right) of ex vivo expanded DNTs and donor-matched Vδ2 T cells 13 days postexpansion (n=6). Purity of cellular products (CD3⁺CD4⁺CD8⁺ for DNTs and CD3⁺γδTCR⁺ for Vδ2 T cells) was determined by flow cytometry. Paired dots indicate donor-matched samples. Paired Student's t-test was used for statistics. (E) Volcano plot of top differential markers between bulk (top) and *TRDV2*⁺ (log₂ FC>1, bottom) cells in DNTs and Vδ2 T cells. Significance cutoffs denoted by the dotted lines are log₂ FC >0.5 and p<10⁻¹⁰. (F) Selected gene set enrichment analysis of differential markers between *TRDV2*⁺ (log₂ FC >1) cells in DNTs and Vδ2 T cells important for cellular immunity. Statistically significant gene sets (p<0.05) are shown. Fisher's exact test was used for statistics. (G) Inferred number of interactions and interaction strength between *TRDV2*⁺ (log₂ FC>1) cells (left) or total cells (right) among DNTs and Vδ2 T cells. (H) Scatterplot comparing the incoming and outgoing interaction strength of inferred ligand-receptor networks between DNT (red) and Vδ2 T-cell (blue) clusters. Size of each dot represents the number of cells, and each dot indicates a cluster. *p<0.05, **p<0.01. DNT, double-negative T-cell; UMAP, uniform manifold approximation and projection.




Figure 4 DNTs feature greater co-stimulatory patterns and cytotoxicity against AML relative to Vδ2 T cells. (A) Relative information flow plot of inferred cellular networks significantly enriched in DNTs (red) or Vδ2 T cells (blue) (left). Over-representation Gene Ontology analysis of network interactions is significantly enriched in DNTs from CellChat (right). Top gene sets are shown. Fisher's exact test and Wilcoxon signed-rank test were used for statistics. (B, C) Visualization circle plot of cluster interactions in DNT and Vδ2 T-cell clusters relating to the IL-2 (B) and CD80/CD86 (C) signaling pathway network. Line thickness denotes interaction strength between clusters. (D) Over-representation Gene Ontology analysis of genes enriched in DNTs (log₂ FC >1) compared with Vδ2 T cells. Top gene sets are shown. (E, F) DNTs or Vδ2 T cells were co-cultured with AML cell lines, MV4-11 and OCI-AML3, for 2 hours at an E:T ratio of 1:1 (E) and 2:1 (F). Levels of IFN γ and TNF α in the supernatants from AML/T-cell co-culture (top) and T-cell alone (bottom) group were measured by ELISA (E). Percentage-specific killing was measured by Annexin V and flow cytometry (F). Each paired dot represents a donor (n=4 for OCI-AML3, n=6 for MV4-11). Two-way ANOVA (E) and paired Student's t-test (F) were used for statistics. nd=not detected, *p<0.05, **p<0.01, ***p<0.001. AML, acute myeloid leukemia; ANOVA, analysis of variance; DNTs, double-negative T-cell; E:T, effector-to-target.

supplemental figure S16), we observed that DNTs secrete 10× and 25× higher levels of IFN γ and TNF α , respectively, when encountering AML targets (figure 4E, top) and lower baseline cytokine secretion when cultured alone (figure 4E, bottom), compared with V δ 2 T cells. Furthermore, DNTs showed significantly greater levels of killing against AML cells relative to donor-matched V δ 2 T cells in vitro (figure 4F). Overall, DNTs demonstrate a better co-stimulatory profile and in vitro cytotoxicity compared with V δ 2 T cells.

DNTs persist longer and demonstrate more durable anti-leukemic function than V δ 2 T cells

One of the factors associated with ACT success is the long-term persistence of T cells.³ To determine the durability of anti-leukemic activity from both products, we first stimulated DNTs and V δ 2 T cells with multiple rounds of AML cells in vitro. DNTs were able to maintain strong anti-leukemic function and control the level of MV4-11

growth significantly better than V δ 2 T cells for at least six rounds of AML stimulation (figure 5A). Similar effects were seen with OCI-AML3 as well (online supplemental figure S17). Next, we investigated whether DNTs could persist longer and provide durable anti-leukemic effects in vivo within AML-engrafted mice. To this end, immune-deficient mice were infused with AML cells followed by injections with an equal number of DNTs or conventional V δ 2 T cells expanded from the same donor. The level of DNTs detected in the blood was 42.5× (14.7×–76.4×) higher than V δ 2 T cells on average, over the course of 14 days after the last T-cell infusion (figure 5B). More importantly, DNT-treated mice had a 64.3% average reduction of AML cells in the bone marrow compared with untreated mice, which was significantly better than the mice treated with V δ 2 T cells (figure 5C). Taken together, these data demonstrated that DNTs persist longer in the recipients and resulted in a more robust anti-AML effect in vivo in




Figure 5 DNTs persist longer and demonstrate more durable anti-leukemic function than V δ 2 T cells. (A) Effector cells, DNTs and V δ 2 T cells, were co-cultured with MV4-11 at an E:T ratio of 2:1. Every 24 hours following co-culture, live target counts were measured, and fresh target cells were added to the co-culture at the original E:T ratio. Data are representative of two independent experiments performed in triplicates. Two-way ANOVA was used for statistics. (B, C) Sublethally irradiated (225 cGy) NSG mice were infused with MV4-11 cells followed by three injections of effector cells. Mice peripheral blood was collected twice a week, and the number of DNTs (red, n=14) and V δ 2 T cells (blue, n=14) was measured by flow cytometry (B). AML bone marrow engraftment levels relative to the untreated group (gray, n=11) were measured by flow cytometry from two pooled experiments. Each dot represents an individual mouse, and error bars indicate mean \pm SD (C). Two (B) and one (C) way ANOVA were used for statistics. * p <0.05, ** p <0.01, *** p <0.001. AML, acute myeloid leukemia; ANOVA, analysis of variance; E:T, effector-to-target; DNT, double-negative T-cell.

comparison to donor-matched V δ 2 T cells expanded with zoledronic acid.

Memory and regulatory qualities in DNTs contribute to longer in vivo persistence

Reduced T-cell exhaustion and increased T-cell memory are well-known characteristics that influence T-cell persistence to maintain durable anti-cancer effects and reduce the incidence of disease relapse.^{3,24} Using an established T_{EX}-cell signature from Anderson *et al.*²⁰ we found that DNTs had lower expression of conventional T_{EX}-cell markers (*TOX*, *LAG3*, and *HAVCR*) and overall T_{EX}-cell signature score than V δ 2 T cells (figure 6A). Notably, populations with minimal T_{EX}-cell values were the clusters expressing partial *TRDVI* and $\alpha\beta$ TCRs in DNTs (figure 3A–C; figure 6A, middle). Next, we examined the memory phenotypes of both cellular products. DNTs expressed higher levels of naïve T-cell (T_{Naive}; figure 6B) and central-memory T (T_{CM})-cell (figure 6C) signatures,²⁰ compared with donor-matched V δ 2 T cells, with strong signals detected in partial *TRDVI*⁺ and $\alpha\beta$ TCR⁺ populations. These observations were confirmed with flow cytometry, detecting significantly higher frequencies of CD62L⁺CD45RA⁺ T_{CM}-cell and CD62L⁺CD45RA⁺ T_{Naive}/SCM⁺-cell phenotypes in DNTs compared with donor-matched V δ 2 T cells (figure 6D). Further analysis between different DNT subsets showed lower levels of T_{EX}-cell signature scores and higher levels of T_{Naive}/SCM⁺-cell features among V δ 1⁺ and $\alpha\beta$ TCR⁺ DNTs (online supplemental figures S18 and S19) and a higher effector-memory phenotype in V δ 2⁺ DNTs (online supplemental figure S19). This aligns with previous observations in which V δ 1⁺ and $\alpha\beta$ TCR⁺ DNTs persisted longer during chronic AML stimulation (figure 2G), while V δ 2⁺ DNTs demonstrated greater cytotoxic features (figure 2E).

Allogeneic cellular therapies can be susceptible to host alloreactive T cells, limiting their in vivo persistence and overall therapeutic effectiveness.⁷ Given that DNTs demonstrated prolonged persistence and previously have displayed immune regulatory capabilities,^{41,42} we examined the regulatory profile of DNTs and V δ 2 T cells to assess their innate ability to avoid HvG rejection by allogeneic T cells. From scRNA-seq analysis, DNTs exhibited greater scores of the T_{Reg}-cell signature from Anderson *et al.* (figure 6E), which supports earlier observations of higher *FOXP3* expression in DNTs compared with V δ 2 T cells (figure 3E). When co-culturing allogeneic PBMCs with DNTs or V δ 2 T cells, we observed that CD4⁺ and CD8⁺ T-cell populations proliferated significantly less in the presence of DNTs relative to V δ 2 T cells (figure 6F). This feature may be primarily attributed to the $\alpha\beta$ TCR⁺ DNT subset, as its depletion impairs the ability of DNTs to suppress allogeneic CD8⁺ T-cell proliferation (online supplemental figure S20).

Next, to determine if DNTs can evade host alloreactivity through their immunosuppressive function, we conducted a mixed lymphocyte reaction. PBMCs were cultured with (stimulated group) or without (non-stimulated group)

irradiated, allogeneic DNTs in the absence or presence of live DNTs or V δ 2 T cells as suppressor cells (figure 6G, top). After 6 days of primary stimulation, CD8⁺ T cells were isolated from the co-cultures and used as effectors against the live allogeneic DNTs from the same donor used in the primary stimulation. CD8⁺ T cells stimulated with irradiated, allogeneic DNTs in the presence of live DNTs exhibited lower alloreactivity than the V δ 2 T cell co-culture group, suggesting that DNTs can better suppress the onset of alloreactivity of conventional T cells in the host (figure 6G, bottom). To compare the ability of both cellular products to escape alloreactivity in vivo, allogeneic PBMCs were co-infused with DNTs or V δ 2 T cells into immune-deficient mice. DNTs were detected for a significantly longer period with an average of >50 cells/mL of blood up to 42 days, while V δ 2 T cells fell below 50 cells/mL after 22 days (figure 6H). Overall, the combination of lower exhaustion and higher memory marker expression, and a better capacity to limit alloreactivity may contribute to the ability of DNTs to persist longer than V δ 2 T cells.

ScRNA-seq identifies a unique DNT signature that resembles the genes preferentially expressed in clinically persistent CAR DNTs

From the scRNA-seq analysis, we identified a unique gene signature in DNTs relative to their V δ 2 T-cell counterparts (figure 7A). Using flow cytometry, we confirmed and validated various extracellular and intracellular molecules to produce a distinct 13-marker DNT signature that highlights the memory function, co-stimulatory nature, and regulatory activity of DNTs, which were differentially expressed relative to V δ 2 T cells (figure 7B).

Recent longitudinal studies monitored CAR T cells in patients with various cancers, who achieved durable remission for 5–10 years.^{18–20} CD3⁺CD4⁺CD8⁺ DNTs were the dominant population within CAR⁺ T cells persisting in circulation at time points up to ~5 years despite the initial infusion of conventional CAR T cells, which contained less than 10% CD3⁺CD4⁺CD8⁺ cells.^{18–20} Using proteomic and transcriptomic data collected from these CAR T-cell studies,^{18–20} we observed that ex vivo expanded DNTs expressed genetic patterns found in these persisting CAR DNTs to a greater degree than V δ 2 T cells (figure 7C). Notably, despite few consistent markers between persisting CAR DNT signatures,^{18–20} an aggregated persisting CAR DNT signature revealed that the partial V δ 1⁺ cluster 2 and 10 in DNTs exhibit most of these persistent genes, which were not observed in the corresponding V δ 2 T-cell clusters (figures 3A–C and figure 7C). Further analysis indicated that *TRDVI*⁺ DNTs featured the greatest CAR DNT scores when using the Melenhorst *et al.*, Anderson *et al.*, and combined signatures, but *TRDV2*⁺ DNTs exhibited the highest CAR DNT score from the Xu *et al.* signature (online supplemental figure S21).^{18–20} Altogether, these data indicate a unique DNT gene signature that shares transcriptional similarities to persistent CAR DNTs, which have manifested in patients with durable remission status.




Figure 6 Memory and regulatory qualities in DNTs may contribute to longer in vivo persistence. (A–C) Volcano plot of top differential markers (cutoffs: \log_2 FC > 0.5 and $p < 10^{-10}$) with different gene labels, and UMAP and violin plots of module scores based on exhaustion T (T_{EX})-cell (A), naïve T (T_{Naive})-cell (B), and central memory T (T_{CM})-cell (C) signatures from Anderson *et al.*²⁰ between DNTs and V δ 2 T cells. Unpaired Student's t-test was used for statistics. (D) Memory phenotype of DNTs and V δ 2 T cells based on CD62L and CD45RA expression by flow cytometry. Representative flow plots and individual T-cell memory phenotypes (n=6) are shown. Each paired dot represents a donor. Naïve/stem cell memory T ($T_{Naive/SCM}$) cell = CD62L⁺CD45RA⁺, central memory T (T_{CM}) cell = CD62L⁺CD45RA⁺, effector memory T (T_{EM}) cell = CD62L⁺CD45RA⁺, effector T ($T_{Effector}$) cell = CD62L⁺CD45RA⁺. Paired Student's t-test was used for statistics. (E) Volcano plot of top differential markers (cutoffs: \log_2 FC > 0.5 and $p < 10^{-10}$), and UMAP and violin plots of module scores based on regulatory T (T_{Reg}) cell signature from Anderson *et al.*²⁰ between DNTs and V δ 2 T cells. Unpaired Student's t-test was used for statistics. (F) Allogeneic PBMCs were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with or without anti-CD3/CD28 antibody in the presence or absence of ex vivo expanded DNTs or V δ 2 T cells (n=4) at a ratio of 1:1 or 2:1. Cells were harvested, and the CD4⁺ and CD8⁺ T_{conv}-cell populations of the allogeneic PBMCs were assessed for inhibition of proliferation by CFSE dilution using flow cytometry. The data show the percentage of non-proliferating responder cells remaining after 5 days in culture. Red dotted line displays the average non-proliferating levels of allogeneic T_{conv} cells alone with (stim) and without (no stim) anti-CD3/CD28 antibody stimulation. Each paired dot represents a donor. Paired Student's t-test was used for statistics. (G) PBMCs were co-cultured with (stim) or without (non-stim) irradiated allogeneic DNTs as stimulators in the presence or absence of viable DNTs or V δ 2 T cells as suppressors for 6 days. Afterward, allogeneic CD8⁺ T cells were sorted from the co-culture and cultured with live DNT targets in an overnight assay. Percentage-specific killing of DNTs by allogeneic CD8⁺ T cells under different co-culture conditions is shown. Schematic of the mixed lymphocyte reaction experiment (top) and percentage specific killing by allogeneic CD8⁺ T cells against DNT targets following different co-culture conditions (bottom). Experiments were performed in triplicates, and data are representative of two independent experiments. Mean \pm SEM is shown. One-way ANOVA was used for statistics. (H) Sublethally irradiated (225 cGy) NSG mice were infused with 2×10^7 DNTs or V δ 2 T cells expanded from the same donor and 1×10^6 allogeneic PBMCs. Mice were bled, and circulating DNTs (n=5) or V δ 2 T cells (n=5) were counted throughflow cytometry for up to 42 days. Data shown are representative of two independent experiments. Error bars represent mean \pm SEM. Two-way ANOVA was used for statistics. ns=nonsignificant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. ANOVA, analysis of variance; DNT, double-negative T-cell; PBMCs, peripheral blood mononuclear cells.




Figure 7 ScRNA-seq identifies a unique DNT signature that resembles the genes preferentially expressed in clinically persistent CAR DNTs. (A, B) Representative heat map (A) and flow cytometry histograms (B) of DNT signature markers (yellow highlight) between DNTs (red) and donor-matched Vδ2 T cells (blue). Data are representative of at least three donors, and each paired dot indicates a donor. FMO control (black) is shown. Graphs show the mean fluorescence intensity (MFI) of protein expression relative to DNTs. Paired Student's t-test was used for statistics. (C) UMAP and violin plots of module scores based on persisting CAR T-cell genes from Melenhorst *et al.*¹⁸ (*TRDC*, *TRDV1*, *TRGV4*, *IKZF2*, *GZMB*, *CD244*), Xu *et al.*¹⁹ (*HLA-DRA*, *HLA-DRB1*, *CCR7*, *CD27*, *CD28*, *LAMP1*), Anderson *et al.*²⁰ (*FXFD2*, *HMOX1*, *GPR183*, *TIGIT*, *HLA-DRA*, *AC004585.1*, *TMEM155*, *FCMR*, *MTSS1*, *TTN*, *DENND2D*, *NUCB2*, *EOMES*, *CAV1*, *LYAR*, *ANTXR2*, *PASK*, *CEP128*, *CMTM7*, *ABHD17B*, *LIMD2*, *GNA12*), and combined genes. Unpaired Student's t-test was used for statistics. **p*<0.05, ***p*<0.01, ****p*<0.001, *****p*<0.0001. DNTs, double-negative T-cell.

DISCUSSION

In this study, we characterized the transcriptional and functional profile of human DNTs. DNTs exhibited three major subsets ($V\delta 2^+$, $V\delta 1^+$, and $\alpha\beta TCR^+$), each with individual genetic features and functional properties that work together to elicit a profound anti-AML response.

$V\delta 2^+$ T cells and their highly conserved $\gamma 9$ subset are the predominant $\gamma\delta$ T-cell population found in peripheral blood with broad anti-tumor activity and no induction of GvHD in allogeneic settings.²⁶ Although $V\delta 2$ T-cell recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT) correlates with better patient outcomes,⁴³ clinical trials infusing allogeneic $V\delta 2$ T cells¹² or stimulating $V\delta 2$ T cells in vivo with zoledronic acid and IL-2¹¹ show variable responses among patients and suggest the need for greater efficacy. Given that over 60% of DNTs express $V\gamma 9V\delta 2$, we compared the $TRDV2^+$ subset in DNTs with donor-matched $V\delta 2$ T cells expanded with zoledronic acid, the most common method to expand clinical $V\gamma 9V\delta 2^+$ T cells.¹² As reported by others, differences in ex vivo expansion methods and co-stimulation can influence T-cell effector function.⁴⁴ Here, we observed that $TRGV9^+TRDV2^+$ DNTs are enriched in cell-killing genes and pathways, similar to $V\delta 2$ T cells. Yet, DNTs displayed greater anti-leukemic activity than $V\delta 2$ T cells both in vitro and in vivo. This may be due to the unique expansion method of DNTs that triggered a cellular response to hypoxia (online supplemental figure S14) and favorable T-cell memory phenotype, increasing cytotoxicity against cancer and cellular persistence, respectively.^{24,45} Furthermore, $TRDV2^+$ DNTs potentially received greater levels of co-stimulation from other DNT subsets, not found in the $V\delta 2$ T cells, to strengthen their cytotoxic function, as depleting $V\delta 2^-$ DNT subsets reduced the overall cytotoxic capacity of $V\delta 2^+$ DNTs against chronic exposure to AML. The $V\delta 2$ T cells also appeared to be more overactivated compared with DNTs, leaving them more susceptible to exhaustion and apoptosis,⁴⁶ based on higher baseline cytokine secretion and lower cytokine release after AML stimulation. Therefore, cellular therapies with pronounced heterogeneous populations such as DNTs may offer stronger anti-tumor capabilities.

$V\delta 1^+$ T cells represent a smaller detectable proportion in peripheral blood, compared with their $V\delta 2^+$ counterparts, and exhibit flexible $V\gamma$ chain pairings. However, they are commonly found in specific tissues such as the skin²⁶ with the potential for stronger anti-cancer function against solid tumors.⁴⁷ Almeida *et al* successfully expanded clinical-grade, polyclonal $V\delta 1$ (DOT) cells, as a potential allogeneic cellular therapy against chronic lymphocytic leukemia (CLL) and AML,^{47,48} which exhibit δ chain pairing with $V\gamma 2/3/4/5/8/9$ chains.⁴⁸ Similarly, our $V\delta 1^+$ DNT subsets pair with $V\gamma 2/4/5/8/9$ and expressed genes related to co-stimulation and some cytotoxic molecules. These features appear to enhance the primarily cytotoxic $V\delta 2^+$ DNT subset and provide greater cellular persistence for the overall DNT product. Interestingly, persisting $V\gamma 4V\delta 1^+$ CAR T cells have been detected in a

CLL patient experiencing ~10 years in continuous remission, and tumor-reactive $V\gamma 2V\delta 1$ were found in a Merkel cell carcinoma patient who achieved a complete response following anti-PD1 therapy.^{18,33} Although the number of patients in these studies is limited, this suggests anti-tumoral differences between $V\delta 1^+$ T cells with varying $V\gamma$ chains and warrants further investigation to optimize its cellular therapeutic effects.

Previously, we and others have expanded human $\alpha\beta TCR^+$ DNTs and characterized their potent immune regulatory activities.^{41,42} Here, in the presence of other DNT subsets, $\alpha\beta TCR^+$ DNTs continue to express T_{Reg} signature genes and function to suppress the proliferation of allogeneic T cells, along with strong T_{Naive} and T_{CM} markers and diverse $\alpha\beta TCR$ repertoire, which allows for response against a broad range of antigens.⁴⁹ GO analysis revealed that $\alpha\beta TCR^+$ DNTs are enriched with T-cell differentiation and activation gene sets, suggesting possible potentiation of $V\delta 2^+$ and $V\delta 1^+$ DNT functions, as their depletion can also influence $V\delta 2^+$ DNT effector function. It is important to note that the infusion of T_{Reg} -like cells may reduce the efficacy of allo-HSCT by disrupting immune effector function, increasing the probability of relapse.⁵⁰ However, DNT populations together are shown to exert a better overall anti-AML effect than $V\delta 2$ T cells. The regulatory capacity of $\alpha\beta TCR^+$ DNTs may contribute to the protection of other DNT subsets from alloreactive T cells and HVG rejection, allowing for overall greater cellular persistence and anti-leukemic activity of cytotoxic DNT populations. The various subsets of DNTs working in concert may be the key factor underlying its robust therapeutic qualities.

Interestingly, three independent, long-term, follow-up studies involving conventional $CD4^+/CD8^+$ CAR T-cell therapy observed persistent CAR T cells exhibiting a DNT phenotype in patients with durable cancer remission.^{18–20} Five of the patients were those who had achieved the longest remission status in their respective ~5year studies.^{19,20} Of note, one patient continued to be in remission for ~10 years.¹⁸ This phenotypic transition may be due to the downregulation of CD8 and CD4 co-receptors or rapid expansion of a small population of CAR DNTs present in the initial infusion. Signature markers on these clinically persistent CAR DNTs were genetically similar to various populations in the ex vivo expanded DNTs but were absent in $V\delta 2$ T cells. This suggests that the infusion of ex vivo expanded CAR DNTs may yield better clinical outcomes in patients by avoiding the long conversion period of conventional CAR T cells to CAR DNTs.

In summary, our study demonstrated better expansion and a more durable anti-leukemic effect of allogeneic DNTs, relative to donor-matched $V\delta 2$ T cells, and suggested the potential to outperform zoledronic acid-based $\gamma\delta$ T-cell therapies. This study also identified a unique transcriptional signature of DNTs that may help identify key pathways to improve the therapeutic efficacy of other types of allogeneic ACTs.

Acknowledgements We thank all donors that participated in this study.

Contributors ET, IK, JL and LZ conceived and designed the study experiments. ET, IK, KF, JL, MN, JA and YN conducted experiments. ET prepared the manuscript. IK, KF, YN, MN, JA, MDM, SR, JL and LZ provided feedback and edited the manuscript. LZ is the guarantor.

Funding This study was supported by the Princess Margaret Cancer Centre Innovation Acceleration Fund (IAF #2023-003), the Canadian Cancer Society Impact Grant (grant #704121), Canadian Institutes of Health Research (grant #419699, #191854), and Alberta Cancer Foundation Start-Up Fund.

Competing interests MDM is a consultant for Astellas, Abbvie, and Celgene. SR has received research funding from Wugen, USA and MacroGenics, USA and is an inventor of CD3xCD123 bispecific-related patents for the treatment of hematological malignancies. LZ has financial interests (e.g., holdings/shares) in WYZE Biotech Co and previously received research funding and consulting fee/honorarium from the company. LZ and JL are coinventors of several DNT technology related patents and intellectual properties for the treatment of AML. The remaining authors have declared no conflicts of interest.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by University Health Network Research Ethics Board (05-0221-T). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. The data generated in this study are available within the article and its supplementary material. Single-cell RNA sequencing data are found in online supplemental file 2. All other original data generated in this study are available on request from the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Enoch Tin <http://orcid.org/0000-0001-7838-0400>

Karen Fang <http://orcid.org/0009-0001-6662-7872>

Sergio Rutella <http://orcid.org/0000-0003-1970-7375>

REFERENCES

- Dance A. Cancer immunotherapy comes of age | science | AAAS. 2017. Available: <https://www.science.org/content/article/cancer-immunotherapy-comes-age>
- NCI. CAR T cells: engineering immune cells to treat cancer - NCI. 2022. Available: <https://www.cancer.gov/about-cancer/treatment/research/car-t-cells>
- Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. *Nat Rev Clin Oncol* 2023;20:359–71.
- Lyman GH, Nguyen A, Snyder S, et al. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. *JAMA Netw Open* 2020;3:e202072.
- Graham C, Jozwik A, Pepper A, et al. Allogeneic CAR-T Cells: More than Ease of Access? *Cells* 2018;7:7.
- Lee JB, Kang H, Fang L, et al. Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer. *Clin Cancer Res* 2019;25:2241–53.
- Kang Y, Li C, Mei H. Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting. *J Hematol Oncol* 2024;17:29.
- Sasu BJ, Opitck GJ, Gopalakrishnan S, et al. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. *Mol Ther* 2023;31:676–85.
- Lee JB, Chen B, Vasic D, et al. Cellular immunotherapy for acute myeloid leukemia: How specific should it be? *Blood Rev* 2019;35:18–31.
- Nguyen R, Wu H, Pounds S, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. *J Immunother Cancer* 2019;7:81.
- Kunzmann V, Smetak M, Kimmel B, et al. Tumor-promoting versus tumor-antagonizing roles of $\gamma\delta$ T cells in cancer immunotherapy: results from a prospective phase I/II trial. *J Immunother* 2012;35:205–13.
- Vydra J, Cosimo E, Lesný P, et al. A Phase I Trial of Allogeneic $\gamma\delta$ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 2023;23:e232–9.
- Lee J, Minden MD, Chen WC, et al. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms. *Clin Cancer Res* 2018;24:370–82.
- Tang B, Lee JB, Cheng S, et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study. *American J Hematol* 2022;97.
- Vasic D, Lee JB, Leung Y, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. *Sci Immunol* 2022;7:eabl3642.
- Fang KK-L, Lee J, Khatri I, et al. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells. *J Immunother Cancer* 2023;11:e007277.
- Xiao X, Liu H, Qiu X, et al. CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study. *EClinicalMedicine* 2024;70:102516.
- Melenhorst JJ, Chen GM, Wang M, et al. Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells. *Nature New Biol* 2022;602:503–9.
- Xu J, Wang B-Y, Yu S-H, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. *J Hematol Oncol* 2024;17:23.
- Anderson ND, Birch J, Accogli T, et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. *Nat Med* 2023;29:1700–9.
- Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods* 2019;16:1289–96.
- Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (Camb)* 2021;2:100141.
- Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. *Nat Commun* 2021;12:1088.
- Kang H, Lee JB, Khatri I, et al. Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib. *Cancers (Basel)* 2021;13:5039.
- Kondo M, Izumi T, Fujieda N, et al. Expansion of human peripheral blood $\gamma\delta$ T cells using zoledronate. *J Vis Exp* 2011.
- Hu Y, Hu Q, Li Y, et al. $\gamma\delta$ T cells: origin and fate, subsets, diseases and immunotherapy. *Signal Transduct Target Ther* 2023;8:434.
- Leitner J, Mahasongkram K, Schatzlmaier P, et al. Differentiation and activation of human CD4 T cells is associated with a gradual loss of myelin and lymphocyte protein. *Eur J Immunol* 2021;51:848–63.
- Zhou X, Xue H-H. Generation of memory precursors and functional memory CD8⁺ T cells depends on TCF-1 and LEF-1. *J Immunol* 2012;189:2722.
- Julamanee J, Terakura S, Umemura K, et al. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. *Mol Ther* 2021;29:2677–90.
- Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. *J Exp Med* 2003;198:1369–80.
- Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4⁺Foxp3⁺ regulatory T cells promotes hepatic metastatic tumor growth in mice. *Gastroenterology* 2010;139:1030–40.
- Cai C, Samir J, Pirozyan MR, et al. Identification of human progenitors of exhausted CD8⁺ T cells associated with elevated IFN- γ response in early phase of viral infection. *Nat Commun* 2022;13:7543.

- 33 Lien SC, Ly D, Yang SYC, *et al.* Tumor reactive $\gamma\delta$ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient. *Nat Commun* 2024;15:1094.
- 34 Eschweiler S, Wang A, Ramírez-Suástegui C, *et al.* JAML immunotherapy targets recently activated tumor-infiltrating CD8⁺ T cells. *Cell Rep* 2023;42:112040.
- 35 Sadik A, Somarrivas Patterson LF, Öztürk S, *et al.* IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell* 2020;182:1252–70.
- 36 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* 2020;20:651–68.
- 37 van der Weyden CA, Pileri SA, Feldman AL, *et al.* Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. *Blood Cancer J* 2017;7:e603.
- 38 Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. *Nat Rev Immunol* 2003;3:642–55.
- 39 Gilfillan S, Chan CJ, Cella M, *et al.* DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. *J Exp Med* 2008;205:2965–73.
- 40 Zhao Y, Niu C, Cui J. Gamma-delta ($\gamma\delta$) T cells: friend or foe in cancer development? *J Transl Med* 2018;16:3.
- 41 Achita P, Dervovic D, Ly D, *et al.* Infusion of ex-vivo expanded human TCR- $\alpha\beta$ ⁺ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease. *Clin Exp Immunol* 2018;193:386–99.
- 42 Haug T, Aigner M, Peuser MM, *et al.* Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity. *Front Immunol* 2019;10:883.
- 43 Yue K, Gao H, Liang S, *et al.* Improved V δ 2⁺ T cells recovery correlates to reduced incidences of mortality and relapse in acute myeloid leukemia after hematopoietic transplantation. *Ann Hematol* 2023;102:937–46.
- 44 MacPherson S, Keyes S, Kilgour MK, *et al.* Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function. *Mol Ther Methods Clin Dev* 2022;24:380–93.
- 45 Gropper Y, Feferman T, Shalit T, *et al.* Culturing CTLs under Hypoxic Conditions Enhances Their Cytotoxicity and Improves Their Anti-tumor Function. *Cell Rep* 2017;20:2547–55.
- 46 Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. *EBioMedicine* 2022;77:103941.
- 47 Almeida AR, Correia DV, Fernandes-Platzgummer A, *et al.* Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept. *Clin Cancer Res* 2016;22:5795–804.
- 48 Di Lorenzo B, Simões AE, Caiado F, *et al.* Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells. *Cancer Immunol Res* 2019;7:552–8.
- 49 Porciello N, Franzese O, D'Ambrosio L, *et al.* T-cell repertoire diversity: friend or foe for protective antitumor response? *J Exp Clin Cancer Res* 2022;41:356.
- 50 Nadal E, Garin M, Kaeda J, *et al.* Increased frequencies of CD4(+) CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Leukemia* 2007;21:472–9.